Cixutumumab
- Generic Name
- Cixutumumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 947687-12-9
- Unique Ingredient Identifier
- 2285XW22DR
- Background
Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate.
Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types.
- Associated Conditions
- -
- Associated Therapies
- -
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-12-21
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT01263782
- Locations
- ๐บ๐ธ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study in Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 172
- Registration Number
- NCT01232452
- Locations
- ๐น๐ท
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zeytinburnu, Turkey
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
- Conditions
- Metastatic Esophageal AdenocarcinomaMetastatic Esophageal Squamous Cell CarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaRecurrent Esophageal AdenocarcinomaRecurrent Esophageal CarcinomaRecurrent Esophageal Squamous Cell CarcinomaRecurrent Gastroesophageal Junction AdenocarcinomaStage IV Esophageal Cancer AJCC v7
- Interventions
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 94
- Registration Number
- NCT01142388
- Locations
- ๐บ๐ธ
Mercy Hospital of Tiffin, Tiffin, Ohio, United States
๐บ๐ธProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States
๐บ๐ธMercy Health - Saint Vincent Hospital, Toledo, Ohio, United States
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 72
- Registration Number
- NCT00678769
- Locations
- ๐บ๐ธ
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
๐บ๐ธM D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.